Receptos
is focused on discovering, developing and commercializing therapeutics in immune disorders... Read moreReceptos
is focused on discovering, developing and commercializing therapeutics in immune disorders... Read more
CEO
Add
News
Jan 22, 2017
BioPortfolio
Receptos: Receptos Inc RCPT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250
Sep 28, 2016
Fox Business
Receptos: Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?
Aug 15, 2016
Reuters
Receptos: BRIEF-Vital therapies to appoint Faheem Hasnain to its board of directors
Nov 12, 2015
SAN DIEGO BUSINESS JOURNAL
Receptos: Faheem Hasnain No Longer CEO of Receptos Inc.
Sep 17, 2015
AMERICAN BANKING NEWS
Receptos: Receptos Given Consensus Recommendation of "Hold" by Brokerages (NASDAQ:RCPT)
Sep 01, 2015
WATCH LIST NEWS
Receptos: Receptos Receives $192.33 Consensus Price Target from Brokerages (NASDAQ:RCPT)
Aug 31, 2015
WATCH LIST NEWS
Receptos: Receptos Downgraded to "Sell" at Zacks (RCPT)
Aug 28, 2015
BIOSPACE
Receptos: Celgene Completes Acquisition Of Receptos, Advancing Leadership In Immune-Inflammatory Diseases
Aug 28, 2015
FIERCE PHARMA
Receptos: Celgene nails down $7.2B takeover of Receptos
Aug 28, 2015
PHARAMCEUTICAL TECHNOLOGY
Receptos:
Celgene acquires biopharmaceutical firm Receptos for $7.2bn
